Abstract | BACKGROUND: METHODS AND RESULTS: Outcomes for 2191 TL-PAS patients enrolled into DAPT were assessed. The DAPT coprimary composite end point (death, myocardial infarction [MI], or stroke) was lower with 30 compared with 12 months prasugrel treatment (3.7% versus 8.8%; hazard ratio [HR], 0.407; P<0.001). Rates of death and stroke were similar between groups, but MI was significantly reduced with prolonged prasugrel treatment (1.9% versus 7.1%; HR, 0.255; P<0.001). The DAPT coprimary end point, stent thrombosis, was also lower with longer therapy (0.2% versus 2.9%; HR, 0.063; P<0.001). MI related to stent thrombosis (0% versus 2.6%; P<0.001) and occurring spontaneously (1.9% versus 4.5%; HR, 0.407; P=0.007) were both reduced with prolonged prasugrel. MI rates increased within 90 days of prasugrel cessation after both 12 and 30 months treatment. Composite Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) moderate or severe bleeds were modestly increased (2.4% versus 1.7%; HR, 1.438; P=0.234) but severe bleeds were not more frequent (0.3% versus 0.5%; HR, 0.549; P=0.471) in the prolonged treatment group. CONCLUSIONS: CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT00997503.
|
Authors | Kirk N Garratt, W Douglas Weaver, Ronald G Jenkins, Thomas K Pow, Laura Mauri, Dean J Kereiakes, Kenneth J Winters, Thomas Christen, Dominic J Allocco, David P Lee |
Journal | Circulation
(Circulation)
Vol. 131
Issue 1
Pg. 62-73
(Jan 06 2015)
ISSN: 1524-4539 [Electronic] United States |
PMID | 25400062
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | © 2014 American Heart Association, Inc. |
Chemical References |
- Piperazines
- Platelet Aggregation Inhibitors
- Purinergic P2Y Receptor Antagonists
- Pyridines
- Thiophenes
- thienopyridine
- Prasugrel Hydrochloride
- Paclitaxel
- Aspirin
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Aspirin
(therapeutic use)
- Coronary Disease
(therapy)
- Double-Blind Method
- Drug Therapy, Combination
- Drug-Eluting Stents
- Female
- Humans
- Incidence
- Internationality
- Male
- Middle Aged
- Myocardial Infarction
(epidemiology)
- Paclitaxel
(therapeutic use)
- Piperazines
(therapeutic use)
- Platelet Aggregation Inhibitors
(therapeutic use)
- Prasugrel Hydrochloride
- Purinergic P2Y Receptor Antagonists
(therapeutic use)
- Pyridines
(therapeutic use)
- Thiophenes
(therapeutic use)
- Time Factors
- Treatment Outcome
|